


Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/876,478
Filing Date	06/07/2001
First Named Inventor	John A. Peyman
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	JP-001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T ²
NSB		BINDER, L. et al. "Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties" Mol. Endocrinol. 4: 1060-1068 (1990).	
		BYATT, J. C. et al. "Stimulation of mammogenesis and lactogenesis by recombinant bovine placental lactogen in steroid-primed dairy heifers" J. Endocrinol. 140: 33-43 (1994).	
		CUNNINGHAM, B. C. and WELLS, J. A. "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis" Science 244: 1081-1085 (1989).	
		FORSYTH, I. A. "Comparative aspects of placental lactogens: structure and function" Exp. Clin. Endocrinol. 102: 244-251 (1994).	
		FREEMARK, M. et al. "A unique placental lactogen receptor: implications for fetal growth" Endocrinol. 120: 1865-1872 (1987).	
		GERTLER, A. et al. "Preparation, purification, and determination of the biological activities of 12 N terminus-truncated recombinant analogues of bovine placental lactogen" J. Biol. Chem. 267: 12655-12659 (1992).	
		GOFFIN, V. et al. "Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals" Endocrine Rev. 17: 385-410 (1996).	
		GOLOS, T. G. et al. "Cloning of four growth hormone/chorionic somatomammotropin-related complementary deoxyribonucleic acids differentially expressed during pregnancy in the rhesus monkey placenta" Endocrinol. 133: 1744-1752 (1993).	
		HAMMERSTROM, L. et al. "The immunodepressive effect of human glucoproteins and their possible role in the nonrejection process during pregnancy" Acta Obstet. Gynecol. Scand. 58: 417-422 (1979).	
		LOWMAN, H. B. et al. "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen" J. Biol. Chem. 266: 10982-10988 (1991).	
		LUCK, D. N. et al. "Bioactive recombinant methionyl bovine prolactin: structure-function studies using site-specific mutagenesis" Mol. Endocrinol. 3: 822-823 (1989).	

Examiner Signature	<i>N. Ina S. Ben</i>	Date Considered	11/14/01
--------------------	----------------------	-----------------	----------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/876,478
Filing Date	06/07/2001
First Named Inventor	John A. Peyman
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	JP-001

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, data, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
NID	-	MISRA-PRESS, A. et al. "Complex alternative splicing partially inactivates the human chorionic somatomammotropin-like (hCS-L) gene" J. Biol. Chem. 269: 23220-23229 (1994).	
		NG, F. M. et al. "Insulin potentiating action of synthetic peptides relating to the amino terminal sequence of human growth hormone" Diabetes 23: 943-949 (1974).	
		ORMANDY, C. J. "Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse" Genes Dev. 11:167-78 (1997).	
		REDLINE, R. W. and PATTERSON, P. "Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast" Hum. Pathol. 26: 594-600 (1995).	
		STEPHENSON, M. D. "Frequency of factors associated with habitual abortion in 197 couples" Fertil. Steril. 66: 24-29 (1996).	
		STRASBURGER, C. J. et al. "Indication of different lactogen and somatogen binding sites in the human growth hormone molecule as probed with monoclonal antibodies" Mol. Cell. Endocrinol. 67: 55-62 (1989).	
		STRUMAN, I. et al. "Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis." Proc. Natl. Acad. Sci. U.S.A. 96: 246-251 (1999).	
		TAKEDA, T. et al. "Participation of JAK, STAT and unknown proteins in human placental lactogen-induced signaling: a unique signaling pathway different from prolactin and growth hormone" J. Endocrinol. 153: R1-3 (1997).	

Examiner Signature	<u>Nim JR</u>	Date Considered	<u>11/14/01</u>
--------------------	---------------	-----------------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. * Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

A circular black ink stamp from the Office of the Patent and Trademark Officer. The text "OIPETJ" is curved along the top inner edge. The date "NOV 06 2007" is stamped in the center. The words "PATENT & TRADEMARK OFFICE" are curved along the bottom inner edge.

PTO/SB/08 (105-00)
1/2002 GMB 065 (0C21
MENT OF COMMERCE
OMB control number

RECEIVED
JAN 12 2001
FBI CENTER 100-282

man

(use as many sheets as necessary)

Sheet

1

91

1

Application Number	09/876,478
Filing Date	06/07/2001
First Named Inventor	John A. Peyman
Group Art Unit	1646
Examiner Name	

Attorney Docket Number	JP-001
------------------------	--------

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant; Passages or Relevant Figures, Appar.
		Number	Kind Code ² (if known)			
SW		5,506,107		Cunningham et al.	04/09/1996	Claims 1, 4
		4,363,877		Goodman et al.	12/14/1982	Claim 1
		5,955,346		Wells and Cunningham	09/21/1999	Col. 59, claims 4-6
		6,013,478		Wells and Cunningham	01/11/2000	Table III; example 14
		5,580,723		Wells and Cunningham	12/03/1996	Claims 16, 17, 33
		5,534,617		Cunningham et al.	07/09/1996	Table IX

[illegible]

Examiner
Signature

N₁ mod 1 Ba

Date _____

Considered	Not Considered
<p>1. 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 1.37 1.38 1.39 1.40 1.41 1.42 1.43 1.44 1.45 1.46 1.47 1.48 1.49 1.50 1.51 1.52 1.53 1.54 1.55 1.56 1.57 1.58 1.59 1.60 1.61 1.62 1.63 1.64 1.65 1.66 1.67 1.68 1.69 1.70 1.71 1.72 1.73 1.74 1.75 1.76 1.77 1.78 1.79 1.80 1.81 1.82 1.83 1.84 1.85 1.86 1.87 1.88 1.89 1.90 1.91 1.92 1.93 1.94 1.95 1.96 1.97 1.98 1.99 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 2.33 2.34 2.35 2.36 2.37 2.38 2.39 2.40 2.41 2.42 2.43 2.44 2.45 2.46 2.47 2.48 2.49 2.50 2.51 2.52 2.53 2.54 2.55 2.56 2.57 2.58 2.59 2.60 2.61 2.62 2.63 2.64 2.65 2.66 2.67 2.68 2.69 2.70 2.71 2.72 2.73 2.74 2.75 2.76 2.77 2.78 2.79 2.80 2.81 2.82 2.83 2.84 2.85 2.86 2.87 2.88 2.89 2.90 2.91 2.92 2.93 2.94 2.95 2.96 2.97 2.98 2.99 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 3.31 3.32 3.33 3.34 3.35 3.36 3.37 3.38 3.39 3.40 3.41 3.42 3.43 3.44 3.45 3.46 3.47 3.48 3.49 3.50 3.51 3.52 3.53 3.54 3.55 3.56 3.57 3.58 3.59 3.60 3.61 3.62 3.63 3.64 3.65 3.66 3.67 3.68 3.69 3.70 3.71 3.72 3.73 3.74 3.75 3.76 3.77 3.78 3.79 3.80 3.81 3.82 3.83 3.84 3.85 3.86 3.87 3.88 3.89 3.90 3.91 3.92 3.93 3.94 3.95 3.96 3.97 3.98 3.99 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 4.22 4.23 4.24 4.25 4.26 4.27 4.28 4.29 4.30 4.31 4.32 4.33 4.34 4.35 4.36 4.37 4.38 4.39 4.40 4.41 4.42 4.43 4.44 4.45 4.46 4.47 4.48 4.49 4.50 4.51 4.52 4.53 4.54 4.55 4.56 4.57 4.58 4.59 4.60 4.61 4.62 4.63 4.64 4.65 4.66 4.67 4.68 4.69 4.70 4.71 4.72 4.73 4.74 4.75 4.76 4.77 4.78 4.79 4.80 4.81 4.82 4.83 4.84 4.85 4.86 4.87 4.88 4.89 4.90 4.91 4.92 4.93 4.94 4.95 4.96 4.97 4.98 4.99 5.00 5.01 5.02 5.03 5.04 5.05 5.</p>	

11/14/03

+

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**